Shaping the future of animal health
Virbac group
Finance contact
Investor Relations
Virbac
13e rue LID - BP 27
F 06511 Carros cedex
Fax: +33 4 92 08 76 58
 
Virbac in 3 minutes

Public releases 2015

2015 annual results

Monday, March 14, 2016 

Public release

 

2015 annual results heavily impacted by the United States

Read more

2015 Annual consolidated sales

Thursday, January 14, 2016 

Public release

 

   Annual sales growth of 10.2%, driven by exchange rates and acquisitions
 

Read more

2015 third quarter consolidated sales

Thursday, October 15, 2015 

Public release

 

Virbac : sales grow by 5.5% in the third quarter

 

Read more

2015 half year results

Tuesday, September 15, 2015 

Public release

Half-year results  heavily impacted by the United States

 

Read more

2015 second quarter consolidated sales

Thursday, July 16, 2015 

 

Virbac : sales grow by 18.1% in the first half

Read more

Group's perspectives for 2015 impacted by the industrial situation in the United-States

Tuesday, June 23, 2015 

Public release

 

Group’s perspectives for 2015 impacted by the industrial situation in the United-States

Read more

2015 first quarter consolidated sales

Wednesday, April 15, 2015 

Public release

 

Sales growth of 17.1% in the first quarter

Read more

PEA-PME eligibility of Virbac

Tuesday, March 24, 2015 

Public release

Virbac, listed on Euronext Paris

Read more

Virbac announces the closing of the SENTINEL® brands family acquisition in the United States

Monday, January 05, 2015 

Public release

Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® Flavor Tabs® and SENTINEL® SPECTRUM®, marketed up to now by Novartis Animal Health.

Read more

Share on Facebook Share on Google Print current page